Published Date：Mar.2021
Industry：Chemical & Material
Pages：117 Table Number：134
Single User Price：￥3650.00
Enterprise User Price：￥5600.00
Summary As the world continues to deal with COVID-19, economies are moving into recession, under multiple adverse factors, the GDP of European and American countries in the second quarter suffered a historical contraction. At an annualized rate, the US GDP fell by 32.9% month on month, while the overall GDP of the euro zone fell by 12.1%. Moreover, the economic prospects of Europe and the United States in the third quarter under the epidemic situation are hardly optimistic. The resumption of work and production not only brought economic data back, but also triggered a rebound in the epidemic situation. At present, the United States is still the 'epicenter' of the global epidemic. The total number of confirmed cases has exceeded 4.8 million, and the epidemic situation in some European countries has also rebounded. Affected by this, more than 20 states in the United States have announced the suspension or withdrawal of part of the economic restart plan. Britain and Italy have also decided to extend the state of emergency. The rebound of the epidemic situation has posed considerable risks to the economic prospects of Europe and the United States. In the second quarter of this year, US GDP shrank by 9.5% on a month on month basis, or 32.9% at an annual rate, the largest decline since the 1940s. Data show that the sharp decline in personal consumption is the main drag on the U.S. GDP growth in the second quarter. Compared with the United States, Europe's economic contraction in the second quarter was smaller, but it was also the lowest on record, with Germany and France contracting more than 10%. According to the data released by the Federal Bureau of statistics, Germany's GDP fell by 10.1% in the second quarter after adjusting for prices, seasons and working days, the largest decline since the quarterly economic data were available in 1970. Thanks to the effective control and policy support of the new epidemic, China's economy rebounded sharply in the second quarter. The growth rate of manufacturing industry, which accounted for about 28% of GDP, rebounded sharply to 4.4% from the negative value in the first quarter. Chinese original equipment manufacturers (OEMs) and suppliers are ramping up production. And there are increased investments in digital footprints in manufacturing. OEMs in other parts of the world are offering incentives to drive sales. XYZResearch published a report for global Oncology Biosimilar market in this environment. In terms of revenue, this research report indicated that the global Oncology Biosimilar market was valued at USD XXX million in 2019, and it is expected to reach a value of USD XXX million by 2026, at a CAGR of XX % over the forecast period 2021-2026. Correspondingly, the forecast analysis of Oncology Biosimilar industry comprises of China, USA, Japan, India, Korea and South America, with the production and revenue data in each of the sub-segments. The Biocon aims at producing XX Oncology Biosimilar in 2020, with XX % production to take place in global market, Celltrion Inc. accounts for a volume share of XX %. Regional Segmentation (Value; Revenue, USD Million, 2015 - 2026) of Oncology Biosimilar Market by XYZResearch Include China EU USA Japan India Southeast Asia South America Competitive Analysis; Who are the Major Players in Oncology Biosimilar Market? Biocon Celltrion Inc. Dr. Reddy's Laboratories Intas Pharmaceuticals Ltd. STADA Arzneimittel AG Pfizer Inc. Apotex Inc. Teva Pharmaceutical Industries Ltd. Sandoz International GmbH BIOCAD Mylan F Hoffmann-La Roche ... Major Type of Oncology Biosimilar Covered in XYZResearch report: Lung Cancer Colorectal Cancer Cervical Cancer Breast Cancer Kidney Cancer Stomach Cancer Brain Cancer Others Application Segments Covered in XYZResearch Market Hospital Pharmacies Online Pharmacies Retail Pharmacies Others For any other requirements, please feel free to contact us and we will provide you customized report.
Table of Contents Global Oncology Biosimilar Market Analysis 2020, With Top Companies, Production, Revenue, Consumption, Price and Growth Rate 1 Market Scope 1.1 Product Details and Introduction 1.1.1 Lung Cancer -Product Introduction and Major Manufacturers 1.1.2 Colorectal Cancer -Product Introduction and Major Manufacturers 1.1.3 Cervical Cancer -Product Introduction and Major Manufacturers 1.1.4 Breast Cancer -Product Introduction and Major Manufacturers 1.1.5 Kidney Cancer -Product Introduction and Major Manufacturers 1.1.6 Stomach Cancer -Product Introduction and Major Manufacturers 1.1.7 Brain Cancer -Product Introduction and Major Manufacturers 1.1.8 Others -Product Introduction and Major Manufacturers 1.2 Market Snapshot 1.2.1 Major Companies Overview 1.2.2 Market Concentration 1.2.3 Six-Year Compound Annual Growth Rate (CAGR) 2 Global Oncology Biosimilar Market Assessment, by Segmentation 2.1 Type Breakdown Estimates & Forecast, Sales Volume (2015-2026) 2.2 Type Breakdown Estimates & Forecast, Sales Value (2015-2026) 2.3 Application Breakdown Estimates & Forecast, by Application (2015-2026) 3 Regional Market Analysis 3.1 China Oncology Biosimilar Market 3.1.1 Top Companies leading Oncology Biosimilar Development in China (2015-2020) 3.1.2 Sales Value of Major Company in China Market (2015-2020) 3.1.3 China Oncology Biosimilar Price (USD/Unit), by Type (2019-2020) 3.1.4 Sales in China Market, by Type (2015-2026) 3.2 EU Oncology Biosimilar Market 3.2.1 Top Companies leading Oncology Biosimilar Development in EU (2015-2020) 3.2.2 Sales Value of Major Company in EU Market (2015-2020) 3.2.3 EU Oncology Biosimilar Price (USD/Unit), by Type (2019-2020) 3.2.4 Sales in EU Market, by Type (2015-2026) 3.3 USA Oncology Biosimilar Market 3.3.1 Top Companies leading Oncology Biosimilar Development in USA (2015-2020) 3.3.2 Sales Value of Major Company in USA Market (2015-2020) 3.3.3 USA Oncology Biosimilar Price (USD/Unit), by Type (2019-2020) 3.3.4 Sales in USA Market, by Type (2015-2026) 3.4 Japan Oncology Biosimilar Market 3.4.1 Top Companies leading Oncology Biosimilar Development in Japan (2015-2020) 3.4.2 Sales Value of Major Company in Japan Market (2015-2020) 3.4.3 Japan Oncology Biosimilar Price (USD/Unit), by Type (2019-2020) 3.4.4 Sales in Japan Market, by Type (2015-2026) 3.5 India Oncology Biosimilar Market 3.5.1 Top Companies leading Oncology Biosimilar Development in India (2015-2020) 3.5.2 Sales Value of Major Company in India Market (2015-2020) 3.5.3 India Oncology Biosimilar Price (USD/Unit), by Type (2019-2020) 3.5.4 Sales in India Market, by Type (2015-2026) 3.6 Southeast Asia Oncology Biosimilar Market 3.6.1 Top Companies leading Oncology Biosimilar Development in Southeast Asia (2015-2020) 3.6.2 Sales Value of Major Company in Southeast Asia Market (2015-2020) 3.6.3 Southeast Asia Oncology Biosimilar Price (USD/Unit), by Type (2019-2020) 3.6.4 Sales in Southeast Asia Market, by Type (2015-2026) 3.7 South America Oncology Biosimilar Market 3.7.1 Top Companies leading Oncology Biosimilar Development in South America (2015-2020) 3.7.2 Sales Value of Major Company in South America Market (2015-2020) 3.7.3 South America Oncology Biosimilar Price (USD/Unit), by Type (2019-2020) 3.7.4 Sales in South America Market, by Type (2015-2026) 4 Value Chain (Impact of COVID-19) 4.1 Oncology Biosimilar Value Chain Analysis 4.1.1 Upstream 4.1.2 Downstream 4.2 COVID-19 Impact on Oncology Biosimilar Industry 4.2.1 Industrial Policy Issued Under the Epidemic Situation 4.3 Cost-Under the Epidemic Situation 4.3.1 Cost of Raw Material 4.4 Channel Analysis 4.4.1 Distribution Channel-Under the Epidemic Situation 4.4.2 Distributors 5 Regional Market Forecast (2021-2026) 5.1 Global Oncology Biosimilar Sales and Growth Rate (2021-2026) 5.2 Global Oncology Biosimilar Sales Value and Growth Rate (2021-2026) 6 Oncology Biosimilar Competitive Analysis 6.1 Biocon 6.1.1 Biocon Company Profiles 6.1.2 Biocon Product Introduction 6.1.3 Biocon Oncology Biosimilar Production, Revenue (2015-2020) 6.1.4 SWOT Analysis 6.2 Celltrion Inc. 6.2.1 Celltrion Inc. Company Profiles 6.2.2 Celltrion Inc. Product Introduction 6.2.3 Celltrion Inc. Oncology Biosimilar Production, Revenue (2015-2020) 6.2.4 SWOT Analysis 6.3 Dr. Reddy's Laboratories 6.3.1 Dr. Reddy's Laboratories Company Profiles 6.3.2 Dr. Reddy's Laboratories Product Introduction 6.3.3 Dr. Reddy's Laboratories Oncology Biosimilar Production, Revenue (2015-2020) 6.3.4 SWOT Analysis 6.4 Intas Pharmaceuticals Ltd. 6.4.1 Intas Pharmaceuticals Ltd. Company Profiles 6.4.2 Intas Pharmaceuticals Ltd. Product Introduction 6.4.3 Intas Pharmaceuticals Ltd. Oncology Biosimilar Production, Revenue (2015-2020) 6.4.4 SWOT Analysis 6.5 STADA Arzneimittel AG 6.5.1 STADA Arzneimittel AG Company Profiles 6.5.2 STADA Arzneimittel AG Product Introduction 6.5.3 STADA Arzneimittel AG Oncology Biosimilar Production, Revenue (2015-2020) 6.5.4 SWOT Analysis 6.6 Pfizer Inc. 6.6.1 Pfizer Inc. Company Profiles 6.6.2 Pfizer Inc. Product Introduction 6.6.3 Pfizer Inc. Oncology Biosimilar Production, Revenue (2015-2020) 6.6.4 SWOT Analysis 6.7 Apotex Inc. 6.7.1 Apotex Inc. Company Profiles 6.7.2 Apotex Inc. Product Introduction 6.7.3 Apotex Inc. Oncology Biosimilar Production, Revenue (2015-2020) 6.7.4 SWOT Analysis 6.8 Teva Pharmaceutical Industries Ltd. 6.8.1 Teva Pharmaceutical Industries Ltd. Company Profiles 6.8.2 Teva Pharmaceutical Industries Ltd. Product Introduction 6.8.3 Teva Pharmaceutical Industries Ltd. Oncology Biosimilar Production, Revenue (2015-2020) 6.8.4 SWOT Analysis 6.9 Sandoz International GmbH 6.9.1 Sandoz International GmbH Company Profiles 6.9.2 Sandoz International GmbH Product Introduction 6.9.3 Sandoz International GmbH Oncology Biosimilar Production, Revenue (2015-2020) 6.9.4 SWOT Analysis 6.10 BIOCAD 6.10.1 BIOCAD Company Profiles 6.10.2 BIOCAD Product Introduction 6.10.3 BIOCAD Oncology Biosimilar Production, Revenue (2015-2020) 6.10.4 SWOT Analysis 6.11 Mylan 6.12 F Hoffmann-La Roche 7 Conclusion
List of Tables and Figures Figure Product Introduction Table Production (K Units) and Revenue (Million USD) of Major Players (2015-2020) Figure Global Oncology Biosimilar Production Market Share of Top 5 Players Table CAGR of Major Market (2021-2026) Table CAGR in Terms of Production of Each Type (2015-2026) Table CAGR in Terms of Production of Each Application (2015-2026) Table Global Oncology Biosimilar Sales (K Unit) by Type (2015-2026) Figure Global Oncology Biosimilar Sales (K Unit) and Growth Rate (2015-2026) Figure Global Oncology Biosimilar Sales Market Share (%) by Type (2019 -2020) Table Global Oncology Biosimilar Sales Value (Million USD) by Type (2015-2026) Figure Global Oncology Biosimilar Sales Value (Million USD) and Growth Rate (2015-2026) Figure Global Oncology Biosimilar Sales Value Market Share (%) by Type (2019-2020) Table Global Oncology Biosimilar Sales (K Unit) by Application (2015-2026) Table China Oncology Biosimilar Sales (K Unit) of Major Company (2015-2020) Table China Oncology Biosimilar Sales Market Share of Major Company (2015-2020) Table China Oncology Biosimilar Sales Value (Million USD) of Major Company (2015-2020) Figure China Oncology Biosimilar Sales Value (Million USD) and Growth Rate (2015-2020) Table China Oncology Biosimilar Sales Value Share of Major Company (2015-2020) Table China Oncology Biosimilar Price (USD/Unit), by Type (2019-2020) Table China Oncology Biosimilar Sales (Unit) by Type (2015-2026) Figure China Oncology Biosimilar Sales (Unit) by Type (2015-2026) Table EU Oncology Biosimilar Sales (K Unit) of Major Company (2015-2020) Table EU Oncology Biosimilar Sales Market Share of Major Company (2015-2020) Table EU Oncology Biosimilar Sales Value (Million USD) of Major Company (2015-2020) Figure EU Oncology Biosimilar Sales Value (Million USD) and Growth Rate (2015-2020) Table EU Oncology Biosimilar Sales Value Share of Major Company (2015-2020) Table EU Oncology Biosimilar Price (USD/Unit), by Type (2019-2020) Table EU Oncology Biosimilar Sales (Unit) by Type (2015-2026) Figure EU Oncology Biosimilar Sales (Unit) by Type (2015-2026) Table USA Oncology Biosimilar Sales (K Unit) of Major Company (2015-2020) Table USA Oncology Biosimilar Sales Market Share of Major Company (2015-2020) Table USA Oncology Biosimilar Sales Value (Million USD) of Major Company (2015-2020) Figure USA Oncology Biosimilar Sales Value (Million USD) and Growth Rate (2015-2020) Table USA Oncology Biosimilar Sales Value Share of Major Company (2015-2020) Table USA Oncology Biosimilar Price (USD/Unit), by Type (2019-2020) Table USA Oncology Biosimilar Sales (Unit) by Type (2015-2026) Figure USA Oncology Biosimilar Sales (Unit) by Type (2015-2026) Table Japan Oncology Biosimilar Sales (K Unit) of Major Company (2015-2020) Table Japan Oncology Biosimilar Sales Market Share of Major Company (2015-2020) Table Japan Oncology Biosimilar Sales Value (Million USD) of Major Company (2015-2020) Figure Japan Oncology Biosimilar Sales Value (Million USD) and Growth Rate (2015-2020) Table Japan Oncology Biosimilar Sales Value Share of Major Company (2015-2020) Table Japan Oncology Biosimilar Price (USD/Unit), by Type (2019-2020) Table Japan Oncology Biosimilar Sales (Unit) by Type (2015-2026) Figure Japan Oncology Biosimilar Sales (Unit) by Type (2015-2026) Table India Oncology Biosimilar Sales (K Unit) of Major Company (2015-2020) Table India Oncology Biosimilar Sales Market Share of Major Company (2015-2020) Table India Oncology Biosimilar Sales Value (Million USD) of Major Company (2015-2020) Figure India Oncology Biosimilar Sales Value (Million USD) and Growth Rate (2015-2020) Table India Oncology Biosimilar Sales Value Share of Major Company (2015-2020) Table India Oncology Biosimilar Price (USD/Unit), by Type (2019-2020) Table India Oncology Biosimilar Sales (Unit) by Type (2015-2026) Figure India Oncology Biosimilar Sales (Unit) by Type (2015-2026) Table Southeast Asia Oncology Biosimilar Sales (K Unit) of Major Company (2015-2020) Table Southeast Asia Oncology Biosimilar Sales Market Share of Major Company (2015-2020) Table Southeast Asia Oncology Biosimilar Sales Value (Million USD) of Major Company (2015-2020) Figure Southeast Asia Oncology Biosimilar Sales Value (Million USD) and Growth Rate (2015-2020) Table Southeast Asia Oncology Biosimilar Sales Value Share of Major Company (2015-2020) Table Southeast Asia Oncology Biosimilar Price (USD/Unit), by Type (2019-2020) Table Southeast Asia Oncology Biosimilar Sales (Unit) by Type (2015-2026) Figure Southeast Asia Oncology Biosimilar Sales (Unit) by Type (2015-2026) Table South America Oncology Biosimilar Sales (K Unit) of Major Company (2015-2020) Table South America Oncology Biosimilar Sales Market Share of Major Company (2015-2020) Table South America Oncology Biosimilar Sales Value (Million USD) of Major Company (2015-2020) Figure South America Oncology Biosimilar Sales Value (Million USD) and Growth Rate (2015-2020) Table South America Oncology Biosimilar Sales Value Share of Major Company (2015-2020) Table South America Oncology Biosimilar Price (USD/Unit), by Type (2019-2020) Table South America Oncology Biosimilar Sales (Unit) by Type (2015-2026) Figure South America Oncology Biosimilar Sales (Unit) by Type (2015-2026) Figure Value Chain Structure of Oncology Biosimilar Table Value Chain Table Key Suppliers of Raw Material/Components Table Key Downstream Customer in Each Application Field Table Industry News List of Oncology Biosimilar Figure Cost Structure of Oncology Biosimilar in 2020 Table Distributors/Traders List Table Regional Market Sales (K Unit) (2021-2026) Table Regional Market Sales Share (2021-2026) Figure Global Oncology Biosimilar Sales (Unit), Growth Rate & Market Share (2021-2026) Table Regional Market Sales Value (Million USD) (2021-2026) Table Regional Market Sales Value Share (2021-2026) Figure Global Oncology Biosimilar Sales Value (Million USD), Growth Rate & Market Share (2021-2026) Table Biocon Profiles Table Biocon Oncology Biosimilar Product Introduction Table Biocon Oncology Biosimilar Sales (Unit), Sales Value (Million USD), Price (USD/Unit) and Gross Profit (2015-2020) Figure Biocon SWOT Analysis Table Celltrion Inc. Profiles Table Celltrion Inc. Oncology Biosimilar Product Introduction Table Celltrion Inc. Oncology Biosimilar Sales (Unit), Sales Value (Million USD), Price (USD/Unit) and Gross Profit (2015-2020) Figure Celltrion Inc. SWOT Analysis Table Dr. Reddy's Laboratories Profiles Table Dr. Reddy's Laboratories Oncology Biosimilar Product Introduction Table Dr. Reddy's Laboratories Oncology Biosimilar Sales (Unit), Sales Value (Million USD), Price (USD/Unit) and Gross Profit (2015-2020) Figure Dr. Reddy's Laboratories SWOT Analysis Table Intas Pharmaceuticals Ltd. Profiles Table Intas Pharmaceuticals Ltd. Oncology Biosimilar Product Introduction Table Intas Pharmaceuticals Ltd. Oncology Biosimilar Sales (Unit), Sales Value (Million USD), Price (USD/Unit) and Gross Profit (2015-2020) Figure Intas Pharmaceuticals Ltd. SWOT Analysis Table STADA Arzneimittel AG Profiles Table STADA Arzneimittel AG Oncology Biosimilar Product Introduction Table STADA Arzneimittel AG Oncology Biosimilar Sales (Unit), Sales Value (Million USD), Price (USD/Unit) and Gross Profit (2015-2020) Figure STADA Arzneimittel AG SWOT Analysis Table Pfizer Inc. Profiles Table Pfizer Inc. Oncology Biosimilar Product Introduction Table Pfizer Inc. Oncology Biosimilar Sales (Unit), Sales Value (Million USD), Price (USD/Unit) and Gross Profit (2015-2020) Figure Pfizer Inc. SWOT Analysis Table Apotex Inc. Profiles Table Apotex Inc. Oncology Biosimilar Product Introduction Table Apotex Inc. Oncology Biosimilar Sales (Unit), Sales Value (Million USD), Price (USD/Unit) and Gross Profit (2015-2020) Figure Apotex Inc. SWOT Analysis Table Teva Pharmaceutical Industries Ltd. Profiles Table Teva Pharmaceutical Industries Ltd. Oncology Biosimilar Product Introduction Table Teva Pharmaceutical Industries Ltd. Oncology Biosimilar Sales (Unit), Sales Value (Million USD), Price (USD/Unit) and Gross Profit (2015-2020) Figure Teva Pharmaceutical Industries Ltd. SWOT Analysis Table Sandoz International GmbH Profiles Table Sandoz International GmbH Oncology Biosimilar Product Introduction Table Sandoz International GmbH Oncology Biosimilar Sales (Unit), Sales Value (Million USD), Price (USD/Unit) and Gross Profit (2015-2020) Figure Sandoz International GmbH SWOT Analysis Table BIOCAD Profiles Table BIOCAD Oncology Biosimilar Product Introduction Table BIOCAD Oncology Biosimilar Sales (Unit), Sales Value (Million USD), Price (USD/Unit) and Gross Profit (2015-2020) Figure BIOCAD SWOT Analysis Table Mylan Profiles Table Mylan Oncology Biosimilar Product Introduction Table Mylan Oncology Biosimilar Sales (Unit), Sales Value (Million USD), Price (USD/Unit) and Gross Profit (2015-2020) Figure Mylan SWOT Analysis Table F Hoffmann-La Roche Profiles Table F Hoffmann-La Roche Oncology Biosimilar Product Introduction Table F Hoffmann-La Roche Oncology Biosimilar Sales (Unit), Sales Value (Million USD), Price (USD/Unit) and Gross Profit (2015-2020)
